A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Background: Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid used in multiple sclerosis and intractable epilepsies. Preclinical studies show CBD has numerous cardiovascular benefits, including a reduced blood pressure (BP) response to stress. The aim of this study was to investigate if CBD reduces BP in humans.

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.

Objective: Cannabidiol (CBD) and Δ(9)-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes.

Research Design And Methods: In this randomized, double-blind, placebo-controlled study, 62 subjects with noninsulin-treated type 2 diabetes were randomized to five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks.

Bariatric surgery does not cure all type 2 diabetes.

Bariatric surgery is a treatment increasingly used for morbid obesity and a significant number of patients undergoing this procedure will have diabetes. While bariatric surgery has been shown to be one of the most effective treatments for long term weight control, it has also been shown that it leads to improvements in comorbidities associated with obesity including type 2 diabetes. In fact one large series showed that over 80% of patients treated with gastric bypass procedures no longer required treatment for their diabetes.